Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI

Neurology

Volumn 48, Issue 5, 1997, Pages 1446-1448

  Calabresi, Peter A ^a   Stone, L A ^c   Bash, C N ^b   Frank, J A ^b   McFarland, H F ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON BETA SERINE;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN SCINTISCANNING; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0030988572     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.48.5.1446     Document Type: Article

References (10)

1. The IFNB multiple sclerosis study group. Interferon beta-1b is effective in relapsing remitting multiple sclerosis I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
2. Paty DW, Li DKB, MS/MRI Study Group, IFN-β MS Study Group. Interferon beta 1b is effective in relapsing and remitting multiple sclerosis 2: MRI analysis results of a multicenter, randomized, double-blind, placebo controlled trial. Neurology 1993;43:662-667.
3. Dayal AS, Jensen MA, Lledo A, Arnason BGW. Interferon-gamma secreting cells in multiple sclerosis patients treated with interferon-beta 1b. Neurology 1995;45:2173-2177.
4. Rudge P, Miller D, Crimlisk H, Thorpe J. Does interferon beta cause initial exacerbation of multiple sclerosis? Lancet 1995; 345:580.
5. Rieckmann P, Weber F, Gunther A, Poser S. The phosphodiesterase inhibitor pentoxifylline reduces early side effects of interferon beta 1b treatment in patients with multiple sclerosis. Neurology 1996;47:604.
6. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995;37: 611-619.
7. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
8. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
9. McCarron RM, Wang L, Racke RK, McFarlin DE, Spatz M. Cytokine-regulated adhesion between encephalitogenic T lymphocytes and cerebrovascular endothelial cells. J Neuroimmunol 1992;43:23-30.
10. Barkhof F, Frequin ST, Hommes OR, et al. A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Neurology 1992;42:63-67.